EUVIMEDEUVIMED entdecken
Open Access

Concomitant Use of Selective Serotonin Reuptake Inhibitors With Oral Anticoagulants and Risk of Major Bleeding

Alvi A Rahman, Robert W Platt, Sarah Beradid, Jean-François Boivin, Soham Rej, Christel Renoux

JAMA Network Open · 22.03.2024 · 7 (3) · e243208

DOI: 10.1001/jamanetworkopen.2024.3208 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 22.03.2024. Verfasst von Alvi A Rahman und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec, Canada. Hauptthemen laut MEDLINE: Atrial Fibrillation, Selective Serotonin Reuptake Inhibitors. Die Arbeit wurde bisher 61-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: CIHR.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Selective serotonin reuptake inhibitors (SSRIs) are commonly prescribed antidepressants associated with a small increased risk of major bleeding. However, the risk of bleeding associated with the concomitant use of SSRIs and oral anticoagulants (OACs) has not been well characterized.

Objectives

To assess whether concomitant use of SSRIs with OACs is associated with an increased risk of major bleeding compared with OAC use alone, describe how the risk varies with duration of use, and identify key clinical characteristics modifying this risk. Design, Setting, and Participants A population-based, nested case-control study was conducted among patients with atrial fibrillation initiating OACs between January 2, 1998, and March 29, 2021. Patients were from approximately 2000 general practices in the UK contributing to the Clinical Practice Research Datalink. With the use of risk-set sampling, for each case of major bleeding during follow-up, up to 30 controls were selected from risk sets defined by the case and matched on age, sex, cohort entry date, and follow-up duration. Exposures Concomitant use of SSRIs and OACs (direct OACs and vitamin K antagonists [VKAs]) compared with OAC use alone. Main Outcomes and Measures The main outcome was incidence rate ratios (IRRs) of hospitalization for bleeding or death due to bleeding.

Results

There were 42 190 patients with major bleeding (mean [SD] age, 74.2 [9.3] years; 59.8% men) matched to 1 156 641 controls (mean [SD] age, 74.2 [9.3] years; 59.8% men). Concomitant use of SSRIs and OACs was associated with an increased risk of major bleeding compared with OACs alone (IRR, 1.33; 95% CI, 1.24-1.42). The risk peaked during the initial months of treatment (first 30 days of use: IRR, 1.74; 95% CI, 1.37-2.22) and persisted for up to 6 months. The risk did not vary with age, sex, history of bleeding, chronic kidney disease, and potency of SSRIs. An association was present both with concomitant use of SSRIs and direct OACs compared with direct OAC use alone (IRR, 1.25; 95% CI, 1.12-1.40) and concomitant use of SSRIs and VKAs compared with VKA use alone (IRR, 1.36; 95% CI, 1.25-1.47). Conclusions and Relevance This study suggests that among patients with atrial fibrillation, concomitant use of SSRIs and OACs was associated with an increased risk of major bleeding compared with OAC use alone, requiring close monitoring and management of risk factors for bleeding, particularly in the first few months of use.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationSelective Serotonin Reuptake InhibitorsAgedFemaleHumansMaleAnticoagulantsCase-Control StudiesHemorrhageAged, 80 and over

Substanzen

AnticoagulantsSelective Serotonin Reuptake Inhibitors

Autor:innen und Institutionen

  • Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec, Canada.
  • Centre for Clinical Epidemiology, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada.
  • Department of Pediatrics, McGill University, Montreal, Quebec, Canada.
  • Department of Psychiatry, McGill University, Montreal, Quebec, Canada.
  • Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec, Canada.
  • Department of Medicine, McGill University, Montreal, Quebec, Canada.

Förderung

  • CIHR

Zitieren

APA

Rahman, A. A., Platt, R. W., Beradid, S., Boivin, J. F., Rej, S., & Renoux, C. (2024). Concomitant Use of Selective Serotonin Reuptake Inhibitors With Oral Anticoagulants and Risk of Major Bleeding. JAMA Network Open, 7(3), e243208. https://doi.org/10.1001/jamanetworkopen.2024.3208

Vancouver

Rahman AA, Platt RW, Beradid S, Boivin JF, Rej S, Renoux C. Concomitant Use of Selective Serotonin Reuptake Inhibitors With Oral Anticoagulants and Risk of Major Bleeding. JAMA Network Open. 2024;7(3):e243208. doi:10.1001/jamanetworkopen.2024.3208

BibTeX
@article{Rahman2024,
  author = {Rahman, Alvi A and Platt, Robert W and Beradid, Sarah and Boivin, Jean-François and Rej, Soham and Renoux, Christel},
  title = {Concomitant Use of Selective Serotonin Reuptake Inhibitors With Oral Anticoagulants and Risk of Major Bleeding},
  journal = {JAMA Network Open},
  year = {2024},
  volume = {7},
  number = {3},
  pages = {e243208},
  doi = {10.1001/jamanetworkopen.2024.3208}
}
Kostenlos starten →